- Fusions involving BCR and TCR loci, including IGH, IGL and IGK, are targeted for expression and may not be explicitly called as a fusion because these often do not result in chimeric transcripts
- Targets are listed for primary purpose but may detect other mutation types
- ABC and GCB DLBCL signature genes are targeted for expression. An experimental classification tool for ABC/GCB differentiation is available in Archer Analysis
Liquid Biopsy Tests

The Archer® LiquidPlex RUO panel for Illumina® is an advanced and user-friendly solution for targeted next-generation sequencing (NGS) of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly associated with solid tumor type cancers.
- Key Features
- Specifications
- Gene Targets
- Additional Resources
- Assays
Relevant Fragment Capture
Anchored Multiplex PCR (AMP™)-based target enrichment preferentially enriches for highly fragmented ctDNA over high molecular weight genomic DNA to reduce background and increase detection sensitivity of low-allele fraction (AF) mutations.
Single-Day Library Prep
NGS-ready libraries can be prepared in under 8 hours with less than 1 hour of hands-on time, providing sequencing results in as little as 3 days.
Error Correction & Quantitative Analysis
Molecular barcode sequences ligated prior to amplification enable duplicate read binning and advanced error correction for confident variant calls.
Sensitive & Specific Variant Detection
Reliably detect high AF (5%) variants using as little as 5ng total cfDNA input and low AF (1%) variants from as little as 10ng.
28
Gene Targets
> 5ng
Input cfDNA Required
100%
Target Bases Covered
> 90%
Raw Molecular On-Target
1 Hour
Hands-On Time
1 Day
Total Time
Illumina
Platform
- TNFRSF13B
- AKT1
- ALK
- AR
- BRAF
- CTNNB1
- DDR2
- EGFR
- ERBB2
- ESR1
- FGFR1
- HRAS
- DH1
- IDH2
- KIT
- KRAS
- MAP2K1
- MAP2K2
- MET
- MTOR
- NRAS
- NTRK1
- NTRK3
- PDGFRA
- PIK3CA
- RET
- ROS1
- SMAD4
- TPS3
- TNFSF13B
- TNFRSF13B
- TNFRSF13B
